Endometrial hyperplasia: Risks, recognition and the search for a safe hormone replacement regimen

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 44, Issue 2 SUPPL., 1999, Pages 191-196

  De Lignieres, Bruno ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Endometrial hyperplasia; Hormone replacement, post menopausal; Progesterone

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE;

CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ENDOMETRIAL HYPERPLASIA; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROGESTERONE CONGENERS; RISK FACTORS;

EID: 0033013049     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. de Lignieres B, Moyer DL: Influence of sex hormones on hyperplasia/carcinoma risks. In Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Edited by RA Lobo. New York, Raven Press, 1994, pp 373-383
2. Spencer CP, Cooper AJ, Whitehead MI: Management of abnormal bleeding in women receiving hormone replacement therapy. Br Med J 1997;315:37-42
3. Gambrell RD Jr: Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 1997;177:1196-1207
4. Pike MC, Peters RK, Cozen W, et al: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-1116
5. Shapiro JA, Weiss NS, Beresford SAA, et al: Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 1998;9:99-101
6. The Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275: 370-375
7. American Cancer Society: Cancer Facts & Figures, 1997. Atlanta, ACS, 1997
8. Grady D, Ernster VL: Hormone replacement therapy and endometrial cancer: Are current regimens safe (edit)? J Natl Cancer Inst 1997;89:1088-1089
9. Magos AL, Brewster F, Singh R, et al: The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: A model for the premenstrual syndrome. Br J Obstet Gynaecol 1986;93:1290-1296
10. Sturdee DW, Barlow DH, Ulrich LG, et al: Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? Lancet 1994;344:979-982
11. Moyer DL, de Lignieres B, Driguez P, et al: Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: Influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992-997
12. Marengo M, Rodriguez VD, Gil DE: Hormonal replacement therapy (HRT): Evaluation of a novel 25 days regimen with percutaneous estradiol (PE2) and micronized oral progesterone (MP) (abstr). In Proc of the 8th International Congress on Menopause, Sydney, November 3-7, 1996
13. Gillet JY, Andre G, Faguer B, et al: Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose: A multicenter study. Maturitas 1994;19: 103-115
14. Foidart JM, Dombrowicz D, Roelandt L, et al: Impact on the endometrium of hormone replacement with combined progesterone and percutaneous estradiol. In Proc of 4th International Symposium on Osteoporosis. Edited by C Christiansen, B Riis. Aalborg, Denmark, APS, 1993, pp 331-333